MedTrace Logo

Role of Activated Charcoal in Decreasing Blood Urea, Creatinine and Phosphorous

NCT04311645 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2020-05-14

No results posted yet for this study

Summary

The study aims to explore the ability of Oral activated charcoal to adsorb uremic toxins limiting the progression of chronic kidney disease and delaying the need for hemodialysis in patients with CKD stages III and IV.

To compare its effect with the effect of dry seeds as absorbents of uremic toxins

Conditions

  • Chronic Kidney Disease stage3

Interventions

DRUG

Activated charcoal

Activated charcoal

DIETARY_SUPPLEMENT

Dry seeds

Dry seeds

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2021-07-01
Completion
2021-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04311645 on ClinicalTrials.gov